HeraMED Ltd. (AU:HMD)
ASX:HMD
Want to see AU:HMD full AI Analyst Report?
HMD Stock Chart & Stats
AU$0.04
AU$0.00(0.00%)
At close: 4:00 PM EST
AU$0.04
AU$0.00(0.00%)
Day’s Range― - ―
52-Week Range<AU$0.01 - AU$0.06
Previous CloseN/A
Volume370.09K
Average Volume (3M)1.96M
Market Cap
AU$48.61M
Enterprise ValueAU$22.12M
Total Cash (Recent Filing)AU$914.65K
Total Debt (Recent Filing)AU$282.39K
Price to Earnings (P/E)―
Beta1.98
Next Earnings
Aug 21, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding1,157,486,600
10 Day Avg. Volume1,195,844
30 Day Avg. Volume1,958,766
Financial Highlights & Ratios
PEG Ratio0.16
Price to Book (P/B)27.61
Price to Sales (P/S)131.32
P/FCF Ratio-10.53
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Deleveraged Balance Sheet (zero Debt)The company eliminated debt and reports small positive equity by 2025, reducing near-term default and interest risks. A debt-free position gives financial flexibility to fund operations or restructure financing over the next several months, though the equity cushion remains small versus ongoing losses.
Material Gross Margin ImprovementGross margin recovery to about 60% represents a meaningful improvement in unit economics and suggests product or cost mix gains. This provides a durable lever for future operating leverage: if revenue stabilizes or grows, improved gross margins could translate into faster progress toward operating profitability.
Clear Focus On Digital Maternal HealthThe firm’s core offering—technology-enabled remote maternal monitoring and clinical decision support—aligns with long-term telehealth and women’s health trends. Structural demand for remote prenatal care and data-driven workflows supports recurring software and connected-care adoption over the medium term.
Bears Say
Persistent Negative Operating And Free Cash FlowConsistent negative operating and free cash flow indicates the business consumes cash to run and lacks internal funding to scale. Over a 2–6 month horizon this elevates liquidity and refinancing risk, likely forcing external financing or cost cuts that can impair growth execution.
Consistent Loss-making With Weak MarginsSustained operating and net losses show the company lacks operating leverage despite better gross margins. Persistent negative margins erode equity and limit reinvestment capacity; absent meaningful revenue expansion or cost restructuring, profitability is unlikely in the near term.
Revenue Volatility And Recent ContractionVolatile top-line with recent declines reduces the ability to spread fixed costs and capture operating leverage from improved gross margins. Declining revenue increases short-term cash burn and complicates planning for product investments or sales expansion over the next several months.
HeraMED Ltd. News
HMD FAQ
What was HeraMED Ltd.’s price range in the past 12 months?
HeraMED Ltd. lowest share price was <AU$0.01 and its highest was AU$0.06 in the past 12 months.
What is HeraMED Ltd.’s market cap?
HeraMED Ltd.’s market cap is AU$48.61M.
When is HeraMED Ltd.’s upcoming earnings report date?
HeraMED Ltd.’s upcoming earnings report date is Aug 21, 2026 which is in 74 days.
How were HeraMED Ltd.’s earnings last quarter?
HeraMED Ltd. released its earnings results on Feb 26, 2026. The company reported -AU$0.002 earnings per share for the quarter, missing the consensus estimate of N/A by -AU$0.002.
Is HeraMED Ltd. overvalued?
According to Wall Street analysts HeraMED Ltd.’s price is currently Overvalued.
Does HeraMED Ltd. pay dividends?
HeraMED Ltd. does not currently pay dividends.
What is HeraMED Ltd.’s EPS estimate?
HeraMED Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does HeraMED Ltd. have?
HeraMED Ltd. has 1,157,486,600 shares outstanding.
What happened to HeraMED Ltd.’s price movement after its last earnings report?
HeraMED Ltd. reported an EPS of -AU$0.002 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 5.556%.
Which hedge fund is a major shareholder of HeraMED Ltd.?
Currently, no hedge funds are holding shares in AU:HMD
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
HeraMED Ltd. Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Blogger Sentiment
Bullish
AU:HMD Sentiment 62%
Sector Average ―
Sector Average ―
Insider Transactions
Bought Shares
Worth AU$57.5K over
the Last 3 Months
the Last 3 Months
Technicals
SMA
―
20 days / 200 days
Momentum
100.00%
12-Months-Change
Fundamentals
Return on Equity
-417.72%
Trailing 12-Months
Asset Growth
-68.43%
Trailing 12-Months
Company Description
HeraMED Ltd.
HeraMED Limited and its associated entities are dedicated to the design, production, and sale of at-home fetal heart rate monitors and comprehensive pregnancy monitoring systems. These solutions are offered to consumers throughout Australia, Europe, and Israel. Key products include HeraBEAT, a device enabling expectant mothers to personally track their baby's heartbeat, and HeraCARE, a sophisticated digital platform facilitating the creation and deployment of health solutions for effective maternity care management. The company is also at the forefront of developing EchoBEAT, envisioned as the subsequent evolution of its domestic pregnancy monitoring tools, alongside Orion, an artificial intelligence-driven system engineered for profound pregnancy monitoring analysis. A strategic partnership with Mayo Clinic supports the ongoing advancement of the HeraCARE pregnancy management platform. Established in 2011, HeraMED Limited operates from its main office in Netanya, Israel.
Technical Analysis
Compumedics Limited
―
Impedimed Limited
―
Uscom Limited
―
Atomo Diagnostics Ltd.
―
Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh
―
Options Prices
Currently, No data available
---